Multidisciplinary support at nintedanib initiation is associated with higher 12-month treatment continuation in fibrosing interstitial lung disease: a single-center observational study.

Kinoshita Y, Ogata R, Eshima K, Takenaka S, Hirai C, Ikeda T, Utsunomiya T, Hamaoka H, Higashiyama C, Ohata C, Fukiage Y, Sato K, Matsumoto A, Kushima H, Ishii H

Open source

DOI
10.1016/j.resinv.2026.101504
Published
2026 Sep
Container
Respiratory investigation
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.resinv.2026.101504,
  title = {Multidisciplinary support at nintedanib initiation is associated with higher 12-month treatment continuation in fibrosing interstitial lung disease: a single-center observational study.},
  author = {Kinoshita Y and Ogata R and Eshima K and Takenaka S and Hirai C and Ikeda T and Utsunomiya T and Hamaoka H and Higashiyama C and Ohata C and Fukiage Y and Sato K and Matsumoto A and Kushima H and Ishii H},
  year = {2026},
  journal = {Respiratory investigation},
  doi = {10.1016/j.resinv.2026.101504},
  url = {https://doi.org/10.1016/j.resinv.2026.101504}
}

RIS

TY  - JOUR
TI  - Multidisciplinary support at nintedanib initiation is associated with higher 12-month treatment continuation in fibrosing interstitial lung disease: a single-center observational study.
AU  - Kinoshita Y
AU  - Ogata R
AU  - Eshima K
AU  - Takenaka S
AU  - Hirai C
AU  - Ikeda T
AU  - Utsunomiya T
AU  - Hamaoka H
AU  - Higashiyama C
AU  - Ohata C
AU  - Fukiage Y
AU  - Sato K
AU  - Matsumoto A
AU  - Kushima H
AU  - Ishii H
PY  - 2026
JO  - Respiratory investigation
DO  - 10.1016/j.resinv.2026.101504
UR  - https://doi.org/10.1016/j.resinv.2026.101504
ER  - 

APA

Y, K., R, O., K, E., S, T., C, H., T, I., T, U., H, H., C, H., C, O., Y, F., K, S., A, M., H, K., & H, I. (2026). Multidisciplinary support at nintedanib initiation is associated with higher 12-month treatment continuation in fibrosing interstitial lung disease: a single-center observational study.. Respiratory investigation. https://doi.org/10.1016/j.resinv.2026.101504

Source records